Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc > Webinar $AGN CEO Chris Moreau Tue Apr 16 @ 4PM ET / 1PM PT
View:
Post by bmreed on Apr 10, 2024 2:07pm

Webinar $AGN CEO Chris Moreau Tue Apr 16 @ 4PM ET / 1PM PT

RESCHEDULED: Live Webinar - Algernon Pharmaceuticals $AGN w/ CEO Christopher Moreau

Tuesday, April 16th at 4PM ET / 1PM PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/8317121684104/WN_Jsop9LZ1QgmLjaiRfjcqgQ
 

CEO Chris Moreau will discuss the recent Ifendprodil transaction with Seyltx and plans and milestones for Algernon's DMT stroke research program in 2024 and beyond.

Be the first to comment on this post
Algernon Pharmaceuticals Inc